annb0t
Top 20
With the business potentially at an important milestone, we thought we'd take a closer look at Mesoblast Limited's (ASX:MSB) future prospects. Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. On 30 June 2023, the AU$293m market-cap company posted a loss of US$82m for its most recent financial year. Many investors are wondering about the rate at which Mesoblast will turn a profit, with the big question bein...
>>> Read more: When Will Mesoblast Limited (ASX:MSB) Breakeven?
>>> Read more: When Will Mesoblast Limited (ASX:MSB) Breakeven?
